SecBot SecBot
8-K ·Filed May 13, 2026

MGNX

MACROGENICS INC
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001125345-26-000040
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The business transformation (manufacturing sale + royalty monetization) removes near-term financing overhang and positions MGNX for pipeline catalysts in mid-2026. Traders should watch for MGC026 Phase 1 data in mid-2026, which could be a major inflection point. The stock may re-rate on reduced dilution risk and extended runway.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.16
T+0 close · May 13, 2026 · via day close
Latest settled
−1.92%
T+60 · $4.08
Vs SPY
−5.51%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 14 $4.16entry
  2. T+1 · 6mo ago 0.00%α −0.01% · $4.16
  3. T+5 · 6mo ago +1.92%α +2.64% · $4.24
  4. T+20 · 5mo ago −4.81%α −3.95% · $3.96
  5. T+60 · 3mo ago −1.92%α −5.51% · $4.08
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MacroGenics reported Q1 2026 revenue of $20.8M (up 57% YoY) and net loss of $36.8M, essentially in line with EPS consensus of -$0.57 (actual -$0.58). More importantly, the company announced a manufacturing divestiture and ZYNYZ royalty monetization expected to provide up to $202.5M in non-dilutive capital, extending cash runway through 2028 and reducing near-term financing risk.

Key Financial Metrics

EPS
−$0.58
est −$0.57 · -1.8%
Revenue
$20.8M
+57.5% YoY
Rating
in line

Key Facts

  • Revenue grew 57% YoY to $20.8M driven by contract manufacturing and royalty revenue
  • Net loss narrowed to $36.8M from $41.0M in Q1 2025
  • EPS of -$0.58 vs consensus -$0.57 (in line)
  • Manufacturing operations divestiture to Bora Pharmaceuticals for $122.5M upfront
  • Expanded ZYNYZ royalty monetization with Sagard: $60M received plus up to $20M milestone
  • Cash runway extended through 2028, up from late 2027 prior guidance
  • ADC pipeline on track for multiple data readouts in mid-2026 (MGC026, MGC028, lorigerlimab)
  • Lorigerlimab showed 25% objective response rate in CCGC; ovarian cancer program halted

Financial Impact

Manufacturing divestiture and royalty monetization provide up to $202.5M in non-dilutive capital, significantly reducing dilution risk and extending cash runway through 2028.

cash runwaydilution riskrevenue mix

Risk Factors

  • Manufacturing divestiture closing conditions (expected Q3 2026) - transaction risk
  • Pipeline data readouts are binary events - clinical failure could erase value
  • Partial clinical hold on lorigerlimab LINNET study remains unresolved
  • Sagard milestone payment dependent on ZYNYZ 2026 sales performance

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
62% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001125345-26-000040
Document: mgnx-20260513.htm0001125345-26-000040
Document: 0001125345-26-000040-index-headers.html0001125345-26-000040
Document: 0001125345-26-000040-index.html0001125345-26-000040
Document: 0001125345-26-000040.txt0001125345-26-000040
8-K Data (Synthetic)0001125345-26-000040

Track record

21 reports on MGNX

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +130.41% at T+60 after the Feb 28, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $2.22 Now $2.17 −2.25% settles Feb 12
  2. Nov 13, 20263d ago 8-K Neutral 4/10 Entry $2.31 Now $2.17 −6.06% settles Feb 12
  3. Nov 12, 20264d ago Press Release Bearish 5/10 Entry $2.20 Now $2.17 +1.36% settles Feb 11
  4. Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
  5. Nov 3, 202613d ago 3 Neutral 1/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
  6. Nov 3, 202613d ago 8-K Neutral 2/10 Entry $2.31 Now $2.17 −6.06% settles Feb 2
  7. Oct 26, 202621d ago Press Release Bullish 6/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
  8. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $2.19 Now $2.17 −0.91% settles Jan 22
  9. Oct 22, 202625d ago 144 Neutral 2/10 Entry $2.25 Now $2.17 −3.56% settles Jan 21
  10. Oct 15, 20264w ago Press Release Neutral 3/10 Entry $3.25 Now $2.17 −33.23% settles Jan 13
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 13, 2026